The Michael J. Fox Foundation for Parkinson's Research
  Research
  News & Events
  Funding Programs
  About
PD Online Research
Alzheimer Research Forum
  Current Papers
  ARF Recommends
  Research News
Gene overview of all published PD-association studies for SNCA
Back Search Methods Disclaimer Credits
 Gene: SNCA  (PD1; NACP; PARK1; PARK4; MGC110988)  Entrez Gene    View on AlzGene
 Protein: alpha-synuclein  (alpha-synuclein, isoform NACP140; non A-beta component of AD amyloid; non A4 component of amyloid precursor)  ProteinLink
 Chromosome: 4   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 11 February 2013 ;  ***Note that in addition to SNCA, the gene MMRN1 in this locus shows genome-wide significant effects in PDGene meta-analyses. As statistical significance is currently weaker than for SNCA, MMRN1 is not listed in the top results, but can be accessed via the PDGene search function.***
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      PD Cases Normal Controls  
Study Population Source # Polys # Subjects
(% women)		 DX Onset Age
(range)		 Age
(range)		 # Subjects
(% women)		 Age
(range)		 Result
 Caucasian
Autere, 2002
 Finland CL,PO  1  (detail)  112
(48%)		M--67
(55%)		72.7 + 5.2
(-)		Negative
Botta-Orfila, 2010
 Overlaps with
Mata, 2011 (Spain)		 CL  1  (detail)  757
(43%)		C-68.3 + 10.4
(-)		708
(58%)		69.4 + 13.4
(-)		n.a.
Brighina, 2008
 Overlaps with
Maraganore, 2006		 CL  1  (detail)  361
(35%)		C65.1
(23-88)		70.2
(42-90)		361
(35%)		70.9
(45-93)		n.a.
Cardo, 2011
 Spain CL  1  (detail)  1169
(45%)		C--772
(58%)		64 + 17
(18-100)		Positive
Chung, 2010
 Overlaps with
Maraganore, 2006		 CL  1  (detail)  449
(35%)		-64.7
(23-88)		70.3
(44-90)		449
(35%)		71.8
(45-93)		Trend
Chung, 2010
 USA CL  18  (detail)  449
(35%)		-64.7
(23-88)		70.3
(44-90)		449
(35%)		71.8
(45-93)		Trend
Do, 2011
 USA (23andMe-GWAS) CL  1  (detail)  3426
(40%)		M57.4 + 10.7
(-)		64.3 + 10.6
(-)		29624
(42%)		48.2 + 16
(-)		Positive
Edwards, 2010
 USA (HIHG-GWAS) CL  1  (detail)  604
(37%)		C56.3 + 12.9
(-)		64.5 + 12.1
(-)		619
(66%)		69.3 + 9.8
(-)		Positive
Elbaz, 2010
 Australia (Mellick) CL,PO  4  (detail)  929
(38%)		C59.4 + 11.4
(-)		72.3 + 10.2
(-)		713
(64%)		66.6 + 9.9
(-)		Positive
Elbaz, 2010
 Norway (Aasly) CL  4  (detail)  603
(42%)		C59.3 + 10.9
(-)		73.5 + 10.7
(-)		526
(44%)		71.3 + 12.5
(-)		Positive
Elbaz, 2010
 Overlaps with
IPDGC, 2011 (France/Chartier-Harlin)		 CL  4  (detail)  563
(46%)		C54.7 + 11.5
(-)		63.8 + 10.4
(-)		143
(55%)		65.2 + 11
(-)		Positive
Elbaz, 2010
 Overlaps with
IPDGC, 2011 (Germany/Klein)		 CL  4  (detail)  522
(42%)		C43.9 + 12.9
(-)		61.5 + 12.3
(-)		289
(53%)		54.9 + 13.9
(-)		Positive
Elbaz, 2010
 USA (Wzsolek) CL  4  (detail)  378
(45%)		C62.1 + 11.9
(-)		71 + 11.2
(-)		364
(48%)		72.9 + 10.8
(-)		Positive
Elbaz, 2010
 Ireland (Lynch) CL  4  (detail)  361
(42%)		C51.4 + 10.4
(-)		67.4 + 10.2
(-)		445
(64%)		66.6 + 24.2
(-)		Positive
Elbaz, 2010
 Poland (Opala) CL,PO  4  (detail)  349
(38%)		C57.1 + 11.6
(-)		70.1 + 10.6
(-)		340
(54%)		64.3 + 15.7
(-)		Positive
Elbaz, 2010
 Overlaps with
Simon-Sanchez, 2009 (Germany/Krueger)		 CL,PO  4  (detail)  335
(41%)		C-52.1 + 12.5
(-)		339
(45%)		53.2 + 12.2
(-)		Positive
Elbaz, 2010
 Greece (Hadjigeorgiou) CL  4  (detail)  322
(50%)		C64.6 + 9.4
(-)		68.8 + 9.1
(-)		315
(50%)		70 + 8.6
(-)		Positive
Elbaz, 2010
 Overlaps with
IPDGC, 2011 (Germany/Auberger)		 CL  4  (detail)  232
(49%)		C56.2 + 10.8
(-)		71.9 + 11.4
(-)		47
(36%)		58.8 + 9.8
(-)		Positive
Elbaz, 2010
 Italy (Annesi) CL,PO  4  (detail)  190
(47%)		C61.3 + 9.4
(-)		71.8 + 9.4
(-)		168
(54%)		53.6 + 9.1
(-)		Positive
Elbaz, 2010
 Italy (Valente) CL,PO  4  (detail)  189
(49%)		C58.4 + 8.2
(-)		67.6 + 8.5
(-)		95
(55%)		69 + 9.8
(-)		Positive
Elbaz, 2010
 Greece (Bozi) CL  4  (detail)  135
(41%)		C66.4 + 10.7
(-)		72.6 + 10.4
(-)		95
(56%)		71.3 + 9.5
(-)		Positive
Elbaz, 2010
 Italy (Ferrarese) CL  4  (detail)  103
(47%)		C62.3 + 10.4
(-)		67.8 + 9.6
(-)		102
(38%)		62.1 + 6.6
(-)		Positive
Elbaz, 2010
 Sweden (Wirdefeldt) CL,PO  4  (detail)  91
(44%)		C65.7 + 11
(-)		75.6 + 8.8
(-)		180
(56%)		73.7 + 10.1
(-)		Positive
Farrer, 2001
 Overlaps with
Maraganore, 2006		 CL  5  (detail)  319
(-)		C64
(31-91)		-196
(-)		72
(37-94)		Positive
Ferrarese, 2001
 Italy CL  1  (detail)  38
(-)		C--28
(-)		-Negative
Fung, 2006
 Overlaps with
Simon-Sanchez, 2009 (USA)		 CL  17  (detail)  267
(-)		C--270
(-)		68
(55-88)		n.a.
Gatto, 2010
 USA (PEG) CL,CO  3  (detail)  333
(45%)		C--336
(50%)		-Positive
Goris, 2007
 Overlaps with
IPDGC, 2011 (UK)		 CL  1  (detail)  659
(-)		C--2176
(-)		-n.a.
Hadjigeorgiou, 2005
 Overlaps with
Maraganore, 2006		 CL  1  (detail)  178
(40%)		C63.3 + 9.6
(30-88)		69.5 + 9.7
(44-95)		186
(45%)		68.3 + 11.9
(32-93)		n.a.
Hamza, 2010
 USA (NGRC-GWAS) CL  5  (detail)  2000
(33%)		C58.3 + 11.9
(-)		67.2 + 10.6
(-)		1986
(61%)		70.3 + 14
(21-90)		Positive
Holzmann, 2003
 Germany CL  2  (detail)  315
(44%)		C55.4 + 11.4
(-)		66 + 11.2
(-)		370
(48%)		72 + 4.3
(-)		Negative
IPDGC, 2011
 France (GWAS) CL,PO  1  (detail)  1039
(41%)		U48.9 + 48.9
(-)		-1984
(33%)		73.7 + 5.4
(-)		Positive
IPDGC, 2011
 France (REP-Immuno) CL  1  (detail)  267
(-)		U--363
(-)		-Positive
IPDGC, 2011
 Germany (REP-Immuno) CL  1  (detail)  1153
(-)		U--712
(-)		-Positive
IPDGC, 2011
 Iceland (REP-in silico) CL,PO  1  (detail)  479
(-)		C--1427
(-)		-Positive
IPDGC, 2011
 Netherlands (REP-in silico) CL,PO  1  (detail)  824
(-)		U--2082
(-)		-Positive
IPDGC, 2011
 UK (REP-Immuno) CL  1  (detail)  1271
(-)		U--1864
(-)		-Positive
IPDGC, 2011
 USA (PROGENI/GenePD-GWAS) CL  1  (detail)  876
(40%)		U61.5 + 61.5
(-)		-857
(60%)		-Positive
IPDGC, 2011
 USA (NINDS-GWAS) CL  1  (detail)  971
(40%)		U55.9 + 55.9
(-)		-3034
(53%)		62 + 15.6
(-)		Positive
IPDGC, 2011
 USA (REP-Immuno) CL  1  (detail)  2807
(-)		U--2215
(-)		-Positive
IPDGC, 2011
 Germany (GWAS) CL  1  (detail)  742
(40%)		U56 + 56
(-)		-944
(48%)		-Positive
IPDGC, 2011
 Netherlands (REP-Immuno) CL  1  (detail)  304
(-)		U--402
(-)		-Positive
IPDGC, 2011
 UK (WTCCC-GWAS) CL,PO  1  (detail)  1705
(43%)		U--5200
(50%)		-Positive
Kay, 2008
 USA (Oregon) CL  1  (detail)  601
(35%)		C58 + 11.7
(24-87)		68.1 + 10.3
(30-91)		1220
(62%)		68.9 + 21.9
(20-109)		Positive
Kay, 2008
 USA (Washington) CL  1  (detail)  665
(26%)		C58.5 + 11.8
(25-89)		67.8 + 10.9
(29-95)		560
(64%)		66 + 12.4
(26-99)		Positive
Kay, 2008
 USA (New York) CL  1  (detail)  393
(38%)		C59.7 + 11.6
(29-93)		68.4 + 10.8
(35-95)		271
(63%)		65.5 + 10.7
(34-93)		Positive
Kay, 2008
 USA (Georgia) CL  1  (detail)  143
(37%)		C58.3 + 11.3
(30-92)		67 + 10.2
(39-96)		78
(69%)		68.5 + 8
(50-83)		Positive
Kay, 2010
 Overlaps with
Mata, 2010 (USA-NGRC)		 CL  2  (detail)  2091
(32%)		C58.3 + 12.1
(8-93)		67.3 + 10.7
(21-96)		1686
(56%)		66.1 + 13.1
(25-99)		n.a.
Khan, 2001
 UK CL  2  (detail)  305
(45%)		M57
(-)		61 + 6
(-)		330
(47%)		63 + 7
(-)		Negative
Kruger, 1999
 Overlaps with
Maraganore, 2006 (Germany)		 CL  1  (detail)  236
(44%)		C61.1 + 7.6
(-)		66.5 + 11
(-)		200
(-)		-n.a.
Mamah, 2005
 Overlaps with
Maraganore, 2006		 CL  1  (detail)  161
(-)		C--161
(-)		-n.a.
Maraganore, 2005
 Overlaps with
Chung, 2010 (USA)		 CL  2  (detail)  332
(42%)		C63
(36-88)		68
(42-90)		332
(42%)		67
(42-91)		Negative
Maraganore, 2006
 France (Elbaz) CO  1  (detail)  200
(43%)		C65
(35-75)		69
(37-76)		444
(41%)		69
(36-79)		Positive
Maraganore, 2006
 Italy (Ferrarese) CL  1  (detail)  114
(39%)		C58
(37-77)		67
(44-86)		112
(29%)		66
(48-77)		Positive
Maraganore, 2006
 Greece (Hadjigeorgiou) CO  1  (detail)  152
(40%)		C65
(32-88)		72
(40-95)		120
(47%)		69
(32-89)		Positive
Maraganore, 2006
 Belgium (Van Broeckhoven) CO  1  (detail)  186
(41%)		C57
(28-75)		66
(40-87)		188
(45%)		64
(28-89)		Positive
Maraganore, 2006
 USA (Ashizawa) CL  1  (detail)  100
(41%)		C53
(28-80)		65
(32-84)		100
(51%)		60
(22-75)		Positive
Maraganore, 2006
 USA (Checkoway) CO  1  (detail)  160
(40%)		C65
(35-75)		68
(40-88)		240
(44%)		72
(45-82)		Positive
Maraganore, 2006
 Italy (Quattrone) CO  1  (detail)  190
(42%)		C58
(34-84)		68
(43-88)		181
(55%)		74
(56-93)		Positive
Maraganore, 2006
 Germany (Riess) CL  1  (detail)  163
(44%)		C56
(22-87)		68
(38-91)		738
(49%)		73
(65-83)		Positive
Maraganore, 2006
 Norway (Aasly) CL,PO  1  (detail)  401
(38%)		C60
(25-88)		70
(41-92)		545
(44%)		62
(46-96)		Positive
Maraganore, 2006
 USA (Maraganore) CL,PO  1  (detail)  678
(37%)		C63
(28-88)		68
(31-99)		182
(63%)		72
(37-94)		Positive
Maraganore, 2006
 Australia (Mellick) CL,PO  1  (detail)  373
(45%)		C61
(26-86)		68
(33-89)		375
(70%)		66
(20-89)		Positive
Mata, 2010
 USA (NGRC-Tier1) CL  13  (detail)  685
(-)		C--673
(-)		-Positive
Mata, 2010
 USA (NGRC-Tier2) CL  5  (detail)  1271
(-)		C--1439
(-)		-Positive
Mata, 2011
 Spain CL  1  (detail)  1445
(44%)		C60 + 12.2
(-)		68.1 + 11.2
(-)		1161
(58%)		68.9 + 11.2
(-)		Positive
McCulloch, 2008
 Overlaps with
Kay, 2008 (Oregon)		 CL  1  (detail)  172
(38%)		C-65.9
(39-87)		96
(55%)		67.8
(21-83)		n.a.
McCulloch, 2008
 Overlaps with
Kay, 2008 (Washington)		 CL  1  (detail)  391
(26%)		C-67.3
(32-95)		293
(58%)		67.3
(30-93)		n.a.
McCulloch, 2008
 Overlaps with
Kay, 2008 (New York)		 CL  1  (detail)  253
(35%)		C-68.1
(40-95)		214
(66%)		64.6
(34-94)		n.a.
McCulloch, 2008
 Overlaps with
Kay, 2008 (Georgia)		 CL  1  (detail)  116
(37%)		C-67.3
(40-97)		61
(67%)		68.5
(51-84)		n.a.
Mellick, 2005
 Overlaps with
Maraganore, 2006		 CL  1  (detail)  369
(44%)		C60 + 10
(-)		67 + 10
(-)		370
(69%)		64 + 11
(-)		n.a.
Mueller, 2005
 Overlaps with
Simon-Sanchez, 2009 (Germany-I)		 CL  33  (detail)  340
(42%)		C--680
(-)		-Positive
Mueller, 2005
 Overlaps with
Simon-Sanchez, 2009 (Germany-II)		 CL  16  (detail)  329
(40%)		C--322
(-)		-Positive
Myhre, 2008
 Overlaps with
Elbaz, 2010 (Norway)		 CL  10  (detail)  236
(41%)		C58.2 + 11.4
(-)		69.9 + 10.9
(-)		236
(-)		69.7 + 10.9
(-)		Positive
Pals, 2004
 Belgium CL  18  (detail)  175
(41%)		C57
(28-75)		66
(40-87)		186
(45%)		64
(28-89)		Positive
Pankratz, 2008
 USA (PROGENI, GenePD) CL  110  (detail)  857
(41%)		C61.9 + 10.8
(-)		-867
(60%)		54.8 + 13.1
(-)		Positive
Pankratz, 2009
 Overlaps with
IPDGC, 2011 (USA-GenePD)		 CL  5  (detail)  737
(40%)		C61.8
(18-84)		-359
(56%)		70.3
(55-92)		Positive
Parsian, 1998
 Overlaps with
Parsian, 2007		 CL  1  (detail)  216
(35%)		C--174
(36%)		-n.a.
Parsian, 2007
 USA CL  3  (detail)  521
(36%)		C60.1
(21-85)		68
(-)		215
(42%)		62 + 14
(-)		Positive
Pastor, 2001
 Spain CL  1  (detail)  167
(-)		C56.6 + 11
(-)		-169
(34%)		12
(-)		Negative
Payami, 2009
 Re-analysis of Kay, 2008 CL  1  (detail)  ------n.a.
Rajput, 2009
 Canada CL  4  (detail)  452
(37%)		C62
(-)		71
(41-92)		245
(70%)		65
(18-92)		Positive
Rhodes, 2010
 USA PO  1  (detail)  273
(45%)		C69 + 10.4
(34-88)		-306
(49%)		-Negative
Ross, 2002
 Ireland CL  1  (detail)  98
(48%)		C--92
(70%)		-Negative
Ross, 2007
 Overlaps with
Elbaz, 2010 (Ireland)		 CL  14  (detail)  186
(61%)		C-61 + 12
(-)		186
(61%)		-Positive
Saad, 2010
 France (GWAS) CL  5  (detail)  1039
(41%)		C48.9 + 12.8
(-)		57.5 + 16.6
(-)		1984
(43%)		73.7 + 5.4
(-)		Positive
Saad, 2010
 Overlaps with
Simon-Sanchez, 2009 (WTCCC-GWAS)		 CL  4  (detail)  1705
(42%)		C--5200
(50%)		51
(-)		Positive
Simon-Sanchez, 2009
 USA, Germany, UK (Stage II) CL,PO  8  (detail)  3452
(32%)		M61.1
(-)		-4756
(39%)		-Positive
Simon-Sanchez, 2009
 USA, Germany (GWAS) CL,PO  33  (detail)  1745
(45%)		C55.8
(7-98)		-4047
(50%)		-Positive
Simon-Sanchez, 2009
 USA (NINDS-GWAS) CL  75  (detail)  931
(40%)		C--790
(58%)		-Negative
Simon-Sanchez, 2011
 Netherlands (GWAS) CL,PO  28  (detail)  772
(36%)		U55.3
(16-84)		62.3
(29-89)		2024
(56%)		53.7
(45-95)		Positive
Spadafora, 2003
 Overlaps with
Maraganore, 2006		 CL  1  (detail)  189
(43%)		C-66.2 + 8.7
(-)		182
(55%)		74.9 + 7.5
(-)		n.a.
Spencer, 2010
 Overlaps with
Simon-Sanchez, 2009 (WTCCC-GWAS)		 CL,PO  3  (detail)  1705
(-)		C--5175
(-)		-Positive
Spencer, 2010
 Overlaps with
Saad, 2010 (France-GWAS)		 CL  1  (detail)  1039
(-)		C--1984
(-)		-n.a.
Sutherland, 2009
 Overlaps with
Maraganore, 2006		 CL  9  (detail)  331
(51%)		C60.1 + 10.6
(-)		70.3 + 8.7
(-)		296
(51%)		70.5 + 8.9
(-)		Trend
Tan, 2000
 Overlaps with
Maraganore, 2006		 CL  1  (detail)  100
(-)		C53.4 + 11.5
(28-80)		61 + 12
(32-82)		100
(-)		57.1 + 12.2
(22-74)		n.a.
Trotta, 2011
 Italy CL  10  (detail)  904
(40%)		C56.1 + 11
(-)		66.6 + 10.9
(-)		891
(66%)		62.4 + 14.6
(-)		Positive
Westerlund, 2008
 Sweden CL  3  (detail)  290
(-)		C60.3
(-)		68
(-)		313
(-)		58.3
(-)		Positive
Wider, 2010
 Overlaps with
Elbaz, 2010 (USA)		 CL  1  (detail)  286
(44%)		C62 + 12
(16-85)		73 + 11
(39-92)		322
(45%)		72 + 11
(33-90)		n.a.
Wider, 2010
 Overlaps with
Elbaz, 2010 (Norway)		 CL  1  (detail)  420
(40%)		C59 + 11
(35-88)		73 + 11
(45-99)		464
(44%)		70 + 12
(43-106)		n.a.
Wider, 2010
 Overlaps with
Elbaz, 2010 (Ireland)		 CL  1  (detail)  314
(41%)		C52 + 11
(18-77)		66 + 10
(37-91)		309
(63%)		71 + 23
(23-102)		n.a.
Winkler, 2007
* Recently Updated *		 Overlaps with
Schmitt, 2012 (Germany/Klein)		 CL  14  (detail)  234
(-)		C--160
(-)		-Positive
Winkler, 2007
 Serbia CL  14  (detail)  163
(-)		C--110
(-)		-Positive
Xia, 2001
 USA CL  1  (detail)  53
(-)		C--138
(-)		-Negative
 Asian
Chang, 2011
 China CL  2  (detail)  636
(41%)		C55.8 + 11.1
(17-85)		-510
(43%)		52.4 + 14
(15-91)		Positive
Hu, 2010
 China CL  1  (detail)  330
(46%)		C52.6 + 11.8
(-)		-300
(-)		-Negative
Hu, 2011
 China CL  1  (detail)  110
(45%)		C56.7 + 10.8
(25-79)		59.8 + 10.5
(-)		136
(44%)		59.9 + 9.1
(-)		Positive
Izumi, 2001
 Japan CL  1  (detail)  200
(60%)		C61 + 9.1
(-)		-250
(52%)		61.1 + 13.4
(-)		Negative
Kim, 2010
 Korea CL  1  (detail)  878
(56%)		C56.6 + 9.5
(23-85)		64.2 + 9
(33-91)		559
(54%)		58.5 + 10.6
(37-85)		Positive
Kobayashi, 2006
 Japan CL  22  (detail)  185
(63%)		C62
(28-83)		-191
(65%)		69
(20-92)		Positive
Mizuta, 2002
 Japan CL  1  (detail)  165
(59%)		C56 + 11
(-)		64 + 9.6
(-)		155
(63%)		63 + 8.6
(-)		Negative
Mizuta, 2006
 Overlaps with
Mizuta, 2008		 CL  26  (detail)  882
(56%)		C57.4 + 10.9
(-)		64.9 + 9.8
(-)		938
(48%)		45.3 + 16.3
(-)		Positive
Mizuta, 2008
 Japan (II) CL  1  (detail)  521
(54%)		C58.8 + 11.4
(-)		67.2 + 9.7
(-)		1003
(54%)		-Positive
Mizuta, 2008
 Japan (I) CL  1  (detail)  882
(56%)		C57.4 + 10.9
(-)		-938
(48%)		45.3 + 16.3
(-)		Positive
Satake, 2009
 Japan (Replication-2) CL  4  (detail)  321
(55%)		C63.7 + 9.7
(-)		-1614
(55%)		59.1 + 19.1
(-)		Positive
Satake, 2009
 Japan (Replication-1) CL  4  (detail)  612
(50%)		C43 + 13.8
(20-80)		-14139
(42%)		60.1 + 12.6
(-)		Positive
Satake, 2009
 Japan (GWAS) CL  4  (detail)  1078
(55%)		C-58.8 + 10.1
(22-88)		2628
(45%)		49.9 + 14.2
(-)		Positive
Tan, 2003
 Singapore (I) CL  1  (detail)  104
(45%)		C59 + 10.3
(-)		63.9 + 10.1
(27-88)		105
(45%)		63.8 + 10.2
(26-88)		Trend
Tan, 2003
 Singapore (II) CL  1  (detail)  105
(45%)		C59.1 + 10.6
(-)		64.5 + 9.9
(34-91)		105
(45%)		64.3 + 9.9
(34-93)		Trend
Tan, 2004
 China CL  7  (detail)  214
(44%)		C-64.8 + 9.6
(27-91)		234
(44%)		64.3 + 9.9
(26-92)		Positive
Tan, 2010
 Singapore CL  3  (detail)  433
(44%)		C60
(-)		64
(-)		916
(40%)		56
(-)		Positive
Wang, 2006
 Taiwan CL  2  (detail)  252
(50%)		C-67.6
(37-91)		257
(48%)		60.1
(23-98)		Positive
Wang, 2012
 China CL,PO  1  (detail)  2013
(39%)		C58.6 + 10.4
(-)		62.7 + 10.1
(-)		1971
(42%)		64.9 + 8.3
(-)		Positive
Yu, 2010
 China CL  1  (detail)  332
(-)		C--300
(-)		-Positive
 Other/Mixed
Ding, 2011
 USA CL  1  (detail)  344
(38%)		C61 + 11.5
(-)		66.4 + 10.8
(-)		275
(-)		-Positive
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
      Affecteds Unaffecteds  
Study Population # Polys # Families # Subjects
(% women)		 DX Onset Age
(range)		 Age
(range)		 # Subjects
(% women)		 Age
(range)		 Result
 Caucasian
Brighina, 2008
 Overlaps with
Maraganore, 2006		  1  (detail)  472472
(38%)		C59.5
(31-87)		65.3
(33-91)		472
(49%)		64.4
(32-87)		Positive
Chung, 2010
 USA  19  (detail)   654
(36%)		C60.4
(28-87)		66.3 + 30.8
(-)		654
(50%)		65.1
(32-90)		Trend
Mamah, 2005
 Overlaps with
Maraganore, 2006		  1  (detail)  396396
(-)		U--396
(-)		-n.a.
Maraganore, 2005
 Overlaps with
Chung, 2010 (USA)		  14  (detail)  443443
(39%)		C61
(31-94)		68
(33-96)		443
(52%)		66
(29-90)		Negative
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine PD diagnosis ->  "C" (clinical PD diagnosis), "N" (neuropathological PD diagnosis), "M" (mixed, i.e. PD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
PDGene Recent Updates
PDGene Top Results
*New* Top Results Details
1. MAPT/STH
2. SNCA
3. GBA
4. LRRK2
5. PM20D1
6. GAK
7. MCCC1
8. STK39
9. BST1
10. GPNMB   
[see more]
PDGene Stats
Studies: 881
Genes: 915
Polymorphisms: 3446
Meta-analyses: 889
PDGene Links
GEO-PD Meeting 2012
PDmutDB
Curated by the VIB Department of Molecular Genetics of the University of Antwerp
Parkinson's disease Mutation Database
Curated by Parkinson's Institute from Leiden University Medical Center
Mutation Database for Parkinson's Disease
Curated by the Institute for Infocomm Research in Singapore
Michael J. Fox Foundation
The PDGene database is supported by a grant from The Michael J. Fox Foundation in partnership with the Alzheimer Research Forum.
PD Online Research
Alzheimer Research Forum
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.
Copyright © 2013 Alzheimer Research Forum Disclaimer Copyright